Lin Fan, Chen Zongming Eric, Wang Hanlin L
From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania (Drs Lin and Chen); and the Department of Pathology, University of California, Los Angeles (Dr Wang).
Arch Pathol Lab Med. 2015 Jan;139(1):24-38. doi: 10.5858/arpa.2014-0072-RA.
Immunohistochemistry has become a useful ancillary study in the identification and classification of pancreatic neoplasms. The diagnostic accuracy has been significantly improved because of the continuous discoveries of tumor-associated biomarkers and the development of effective immunohistochemical panels.
To identify and classify pancreatic neoplasms by immunohistochemistry.
Literature review and authors' research data and personal practice experience were used.
To better guide therapeutic decisions and predict the prognostic outcome, it is crucial to make an accurate diagnosis of a pancreatic neoplasm. Application of appropriate immunohistochemical panels enables pathologists to differentiate pancreaticobiliary adenocarcinomas from reactive conditions and to identify rare types of pancreatic neoplasms. Knowing the utilities and pitfalls of each tumor-associated biomarker is essential to avoiding a potential diagnostic error because an absolutely cancer-specific biomarker does not exist. This article reviews frequently used tumor-associated biomarkers, provides lists of effective immunohistochemical panels, and recommends a diagnostic algorithm as a standard approach to pancreatic neoplasms.
免疫组织化学已成为胰腺肿瘤鉴别和分类中一项有用的辅助研究。由于肿瘤相关生物标志物的不断发现以及有效免疫组织化学检测组合的发展，诊断准确性得到了显著提高。
通过免疫组织化学对胰腺肿瘤进行鉴别和分类。
采用文献综述、作者的研究数据及个人实践经验。
为更好地指导治疗决策并预测预后结果，准确诊断胰腺肿瘤至关重要。应用合适的免疫组织化学检测组合可使病理学家将胰胆管腺癌与反应性病变区分开来，并识别罕见类型的胰腺肿瘤。由于不存在绝对癌症特异性生物标志物，了解每种肿瘤相关生物标志物的效用和陷阱对于避免潜在诊断错误至关重要。本文综述了常用的肿瘤相关生物标志物，提供了有效免疫组织化学检测组合列表，并推荐了一种诊断算法作为胰腺肿瘤的标准诊断方法。
